Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG: 9989)
Hong Kong
· Delayed Price · Currency is HKD
3.880
+0.050 (1.31%)
Jan 27, 2025, 11:49 AM HKT
Shenzhen Hepalink Pharmaceutical Group Revenue
Shenzhen Hepalink Pharmaceutical Group had revenue of 1.23B CNY in the quarter ending September 30, 2024, a decrease of -8.80%. This brings the company's revenue in the last twelve months to 5.45B, down -6.46% year-over-year. In the year 2023, Shenzhen Hepalink Pharmaceutical Group had annual revenue of 5.45B, down -23.94%.
Revenue (ttm)
5.45B CNY
Revenue Growth
-6.46%
P/S Ratio
n/a
Revenue / Employee
2.62M CNY
Employees
2,080
Market Cap
14.39B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.45B | -1.71B | -23.94% |
Jan 1, 2023 | 7.16B | 794.23M | 12.48% |
Jan 1, 2022 | 6.37B | 1.03B | 19.38% |
Dec 31, 2020 | 5.33B | 707.42M | 15.30% |
Dec 31, 2019 | 4.62B | -190.31M | -3.95% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Alibaba Health Information Technology | 31.39B |
Innovent Biologics | 8.01B |
Akeso | 2.01B |